Importer of Controlled Substances Application: Akorn, Inc., 60896-60897 [2018-25873]
Download as PDF
<![CDATA[
60896
Federal Register / Vol. 83, No. 228 / Tuesday, November 27, 2018 / Notices
directed to the Secretary to the
Commission and must include a full
statement of the reasons why the
Commission should grant such
treatment. See 19 CFR 201.6. Documents
for which confidential treatment by the
Commission is properly sought will be
treated accordingly. All such requests
should be directed to the Secretary to
the Commission and must include a full
statement of the reasons why the
Commission should grant such
treatment. See 19 CFR 201.6. Documents
for which confidential treatment by the
Commission is properly sought will be
treated accordingly. All information,
including confidential business
information and documents for which
confidential treatment is properly
sought, submitted to the Commission for
purposes of this Investigation may be
disclosed to and used: (i) By the
Commission, its employees and Offices,
and contract personnel (a) for
developing or maintaining the records
By order of the Commission.
Issued: November 20, 2018.
Katherine M. Hiner,
Supervisory Attorney.
[FR Doc. 2018–25749 Filed 11–26–18; 8:45 am
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Registration
ACTION:
Notice of registration.
The registrant listed below
has applied for and been granted
registration by the Drug Enforcement
Administration (DEA) as an importer of
various classes of schedule I or II
controlled substances.
SUPPLEMENTARY INFORMATION: The
company listed below applied to be
registered as an importer of various
basic classes of controlled substances.
Information on the previously published
notice is listed in the table below. No
comments or objections were submitted
and no requests for hearing were
submitted for this notice.
SUMMARY:
Company
FR Docket
Clinical Supplies Management Holdings, Inc .........................
83 FR 39127 ..........................................................................
The DEA has considered the factors in
21 U.S.C. 823, 952(a) and 958(a) and
determined that the registration of the
listed registrant to import the applicable
basic class of schedule I controlled
substance is consistent with the public
interest and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971. The DEA investigated the
company’s maintenance of effective
controls against diversion by inspecting
and testing the company’s physical
security systems, verifying the
company’s compliance with state and
local laws, and reviewing the company’s
background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance
with 21 CFR 1301.34, the DEA has
granted a registration as an importer for
schedule I controlled substances to the
above listed company.
Dated: November 16, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018–25866 Filed 11–26–18; 8:45 am]
amozie on DSK3GDR082PROD with NOTICES1
of this or a related proceeding, or (b) in
internal investigations, audits, reviews,
and evaluations relating to the
programs, personnel, and operations of
the Commission including under 5
U.S.C. Appendix 3; or (ii) by U.S.
government employees and contract
personnel,2 solely for cybersecurity
purposes. All nonconfidential written
submissions will be available for public
inspection at the Office of the Secretary
and on EDIS.3
This action is taken under the
authority of section 337 of the Tariff Act
of 1930, as amended (19 U.S.C. 1337),
and of §§ 201.10 and 210.8(c) of the
Commission’s Rules of Practice and
Procedure (19 CFR 201.10, 210.8(c)).
BILLING CODE 4410–09–P
2 All contract personnel will sign appropriate
nondisclosure agreements.
VerDate Sep<11>2014
17:45 Nov 26, 2018
Jkt 247001
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Akorn, Inc.
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before December 27, 2018 Such
persons may also file a written request
for a hearing on the application on or
before December 27, 2018.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
DATES:
Published
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on May 2,
2018, Akorn Inc., 1222 W. Grand
Avenue, Decatur, Illinois 62522 applied
to be registered as an importer of the
following basic class of controlled
substance:
3 Electronic Document Information System
(EDIS): https://edis.usitc.gov.
PO 00000
Frm 00076
Fmt 4703
Sfmt 4703
August 08, 2018.
E:\FR\FM\27NON1.SGM
27NON1
60897
Federal Register / Vol. 83, No. 228 / Tuesday, November 27, 2018 / Notices
Controlled substance
Drug code
Schedule
Remifentanil .............................................................................................................................................................
9739
II
The company plans to import the
above listed controlled substance for
research purposes.
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Administration (DEA) as bulk a
manufacturer of various classes of
schedule I and II controlled substances.
Dated: November 16, 2018.
John J. Martin,
Assistant Administrator.
[Docket No. DEA–392]
SUPPLEMENTARY INFORMATION:
Bulk Manufacturer of Controlled
Substances Registration
[FR Doc. 2018–25873 Filed 11–26–18; 8:45 am]
ACTION:
BILLING CODE 4410–09–P
Notice of registration.
The registrant listed below
has applied for and been granted
registration by the Drug Enforcement
SUMMARY:
The
company listed below applied to be
registered as bulk manufacturer of
various basic classes of controlled
substances. Information on the
previously published notice is listed in
the table below. No comments or
objections were submitted for this
notice.
Company
FR Docket
Rhodes Technologies .............................................................
83 FR 40567 ..........................................................................
The DEA has considered the factors in
21 U.S.C. 823(a) and determined that
the registration of this registrant to
manufacture the applicable basic classes
of controlled substances is consistent
with the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971. The DEA
investigated the company’s maintenance
of effective controls against diversion by
inspecting and testing the company’s
physical security systems, verifying the
company’s compliance with state and
local laws, and reviewing the company’s
background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the DEA has granted a
registration as a bulk manufacturer to
the above listed company.
Dated: November 16, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018–25875 Filed 11–26–18; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Cambridge Isotope
Laboratories
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before December 27, 2018. Such
persons may also file a written request
for a hearing on the application on or
before December 27, 2018.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
DATES:
Published
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on August
30, 2018, Cambridge Isotope
Laboratories, 50 Frontage Road,
Andover, Massachusetts 01810 applied
to be registered as an importer of the
following basic classes of controlled
substances:
amozie on DSK3GDR082PROD with NOTICES1
Controlled substance
Drug code
Tetrahydrocannabinols ............................................................................................................................................
Gamma Hydroxybutyric Acid ...................................................................................................................................
Morphine ..................................................................................................................................................................
VerDate Sep<11>2014
17:45 Nov 26, 2018
Jkt 247001
PO 00000
Frm 00077
Fmt 4703
August 15, 2018.
Sfmt 4703
E:\FR\FM\27NON1.SGM
27NON1
7370
2010
9300
Schedule
I
I
II
]]>Agencies
[Federal Register Volume 83, Number 228 (Tuesday, November 27, 2018)]
[Notices]
[Pages 60896-60897]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-25873]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Application: Akorn, Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before December 27, 2018
Such persons may also file a written request for a hearing on the
application on or before December 27, 2018.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
requests for hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix to subpart R.
In accordance with 21 CFR 1301.34(a), this is notice that on May 2,
2018, Akorn Inc., 1222 W. Grand Avenue, Decatur, Illinois 62522 applied
to be registered as an importer of the following basic class of
controlled substance:
[[Page 60897]]
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Remifentanil.......................... 9739 II
------------------------------------------------------------------------
The company plans to import the above listed controlled substance
for research purposes.
Dated: November 16, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018-25873 Filed 11-26-18; 8:45 am]
BILLING CODE 4410-09-P
